Mutant-Selective EGFR Inhibitors via Covalent Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR kinase inhibitors, such as Tarceva and Iressa, face challenges with dose-limiting toxicities due to concurrent inhibition of wild-type EGFR, and second-generation covalent inhibitors like BIBW2992 and HKI-272 are ineffective against T790M resistance mutations while causing toxicities.
Innovation Solution
Development of mutant-selective EGFR kinase inhibitors, specifically compounds with a general formula that selectively inhibit T790M and other activating mutations while sparing wild-type EGFR, using a covalent modification mechanism to irreversibly bind to the EGFR kinase domain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EGFR kinase inhibitors (Tarceva, Iressa) are used to treat non-small cell lung cancer, then they show therapeutic effect against activating mutations, but they cause dose-limiting toxicities due to concurrent inhibition of wild-type EGFR
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that selectively interact with mutant EGFR conformations. The compounds contain heterocyclic core structures with specific substituent patterns (R1, R2, R3, R4, R5 groups) that create localized binding preferences for T790M and other activating mutations while avoiding wild-type EGFR binding, thereby achieving mutation-selective inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds including heterocyclic ring types, substituent positions, and chemical groups to optimize selectivity. By adjusting these molecular parameters, the inhibitors achieve enhanced binding affinity for mutant EGFR while maintaining reduced affinity for wild-type EGFR, resolving the toxicity issue.
2Reliability
If second-generation covalent inhibitors (BIBW2992, HKI-272) are used to target T790M resistance mutation, then they show some efficacy, but they cause dose-limiting toxicities and remain ineffective against T790M
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of designing inhibitors that bind to the ATP-binding pocket of EGFR (the standard approach), the compounds are designed to exploit the unique conformational changes in mutant EGFR, particularly the T790M mutation, that alter the binding interface. This inverted strategy allows selective targeting of resistant mutations while avoiding wild-type EGFR.
Solution Approach 2:
The patent uses composite materials by combining multiple heterocyclic structural elements into a single inhibitor molecule. The compounds feature composite heterocyclic cores with multiple substituent groups that work synergistically to achieve high selectivity for T790M and other activating mutations, overcoming the limitations of second-generation inhibitors.
3Adaptability or versatility
If EGFR inhibitors are designed to inhibit wild-type EGFR, then they show broad spectrum activity, but they cannot achieve mutant-selective inhibition
Solution Approach 1:
The patent applies segmentation by dividing the EGFR inhibitor design into distinct functional segments: a heterocyclic core structure that provides mutation-selective binding, and specific substituent groups (R1-R5) that fine-tune selectivity for different activating mutations. This segmented approach allows the inhibitor to selectively target mutants while excluding wild-type EGFR.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate selective inhibition of mutant EGFR, particularly T790M, with significantly higher potency compared to wild-type EGFR, reducing dose-limiting toxicities and effectively targeting resistant mutations, as shown by GI50 values in cellular proliferation assays.
Implementation Method 1
using a covalent modification mechanism to irreversibly bind to the EGFR kinase domain
Data Source
AI summary
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.